S-1033 | CAS#138282-73-2 | FP receptor agonist

MedKoo Cat#: 466085 | Name: S-1033

Description:

WARNING: This product is for research use only, not for human or veterinary use.

S-1033 is an FP receptor agonist.

Chemical Structure

S-1033

CAS#138282-73-2 (sodium)

Theoretical Analysis

MedKoo Cat#: 466085

Name: S-1033

CAS#: 138282-73-2 (sodium)

Chemical Formula: C20H33NaO4

Exact Mass: 360.2277

Molecular Weight: 360.47

Elemental Analysis: C, 66.64; H, 9.23; Na, 6.38; O, 17.75

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

S-1033; S1033; S 1033;

IUPAC/Chemical Name

sodium (E)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((E)-oct-1-en-1-yl)cyclopentyl)hept-5-enoate

InChi Key

WESGECMANBOOPN-ADIIAVBHSA-M

InChi Code

InChI=1S/C20H34O4.Na/c1-2-3-4-5-6-9-12-16-17(19(22)15-18(16)21)13-10-7-8-11-14-20(23)24;/h7,9-10,12,16-19,21-22H,2-6,8,11,13-15H2,1H3,(H,23,24);/q;+1/p-1/b10-7+,12-9+;/t16-,17-,18-,19+;/m1./s1

SMILES Code

O=C([O-])CCC/C=C/C[C@@H]1[C@@H](/C=C/CCCCCC)[C@H](O)C[C@@H]1O.[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 360.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003 Dec;19(6):501-15. doi: 10.1089/108076803322660422. PMID: 14733708. 2: Ando Y, Matsunami C, Yamamoto T, Kitazawa Y. [Safety and ocular hypotensive effect of a new prostaglandin analogue, S-1033, in normal volunteers]. Nippon Ganka Gakkai Zasshi. 1994 Nov;98(11):1109-14. Japanese. PMID: 7825505. 3: Higaki K, Kamata K, Takeuchi M, Inazawa K, Chikai T, Hamaguchi T, Yukawa T, Kadono K, Kawahara S, Nakano M. Ocular absorption, distribution, and systemic absorption of a novel antiglaucoma medication, prostaglandin derivative, in male white rabbits. Drug Metab Dispos. 1995 Jan;23(1):35-43. PMID: 7720522. 4: Kominami G, Nakamura M, Mizobuchi M, Ueki K, Kuroda T, Yamauchi A, Takahashi S. Radioimmunoassay and gas chromatography/mass spectrometry for a novel antiglaucoma medication of a prostaglandin derivative, S-1033, in plasma. J Pharm Biomed Anal. 1996 Nov;15(2):175-82. doi: 10.1016/0731-7085(96)01849-3. PMID: 8933419. 5: Toris CB, Camras CB, Yablonski ME, Brubaker RF. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Surv Ophthalmol. 1997 Feb;41 Suppl 2:S69-75. doi: 10.1016/s0039-6257(97)80010-0. PMID: 9154279. 6: Sharif NA, Kelly CR, Crider JY. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J Ocul Pharmacol Ther. 2002 Aug;18(4):313-24. doi: 10.1089/10807680260218489. PMID: 12222762. 7: Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci. 2003 Feb;44(2):715-21. doi: 10.1167/iovs.02-0323. PMID: 12556403. 8: Sharif NA, Crider JY, Husain S, Kaddour-Djebbar I, Ansari HR, Abdel-Latif AA. Human ciliary muscle cell responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation. J Ocul Pharmacol Ther. 2003 Oct;19(5):437-55. doi: 10.1089/108076803322473006. PMID: 14583136. 9: Sharif NA. Synthetic FP-prostaglandin-induced contraction of rat uterus smooth muscle in vitro. Prostaglandins Leukot Essent Fatty Acids. 2008 Mar;78(3):199-207. doi: 10.1016/j.plefa.2008.01.005. Epub 2008 Mar 28. PMID: 18375109. 10: Sharif NA, Kaddour-Djebbar I, Abdel-Latif AA. Cat iris sphincter smooth- muscle contraction: comparison of FP-class prostaglandin analog agonist activities. J Ocul Pharmacol Ther. 2008 Apr;24(2):152-63. doi: 10.1089/jop.2007.0076. PMID: 18355130.